Purpose: To evaluate the visual and refractive outcomes in patients who underwent bilateral refractive lens exchange (RLE) with the trifocal hydrophobic FineVision HP IOL. Methods: This prospective, single-center, non-comparative study enrolled 70 eyes of 35 patients implanted bilaterally with the FineVision HP IOL (Beaver-Visitec International, Inc. USA). Postoperative outcomes at 3 months included manifest refraction, monocular and binocular logMAR uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), distance-corrected intermediate visual acuity (DCIVA, at 60 cm), and distance-corrected near visual acuity (DCNVA, at 40 cm). The binocular defocus curve was also registered. Results: 94.29% of eyes showed a spherical equivalent within ±0.50D and all within ±1.00D. 95.71% of eyes showed a refractive cylinder of ≤0.50D and all ≤1.00D. The mean spherical equivalent and refractive cylinder were 0.16 ± 0.27D and −0.18 ± 0.21D, respectively. Mean binocular CDVA, DCIVA and DCNVA were −0.12 ± 0.06, 0.15 ± 0.07 and 0.03 ± 0.05 logMAR, respectively. 88.57% and 100% of patients achieved a cumulative binocular CDVA of ≥20/16 and ≥20/20, respectively. Furthermore, 51.43% and 91.43% patients achieved a cumulative binocular DCIVA of ≥20/25 and ≥20/32, respectively; and 71.43% and 100% of patients achieved a cumulative binocular DCNVA of ≥20/20 and ≥20/25, respectively. The safety and efficacy indexes were 1.07 and 1.01, respectively. The defocus curve showed a peak of maximum visual acuity, better than 20/16, at distance, with a continuous smooth reduction in visual acuity for intermediate distances, followed by a secondary peak close to 20/20 at near. Conclusions: The FineVision HP IOL demonstrated favorable short-term refractive accuracy and visual performance in this prospective cohort, although larger comparative studies with longer follow-up are warranted.
Camille Bosc, Eloïse Le Maléfan, Pauline Boury et al.· Clinical Ophthalmology· 0 citations
Purpose To evaluate clinical outcomes in eyes with pre-existing astigmatism undergoing cataract surgery or refractive lens exchange with the implantation of an isofocal optic-design toric intraocular lens (IOL) with double C-loop haptics. Method This multicenter retrospective study comprised 100 eyes (65 patients) implanted with the Isopure Serenity toric IOL (BVI, Inc.) conducted across four sites. Postoperative evaluation at between 2 and 3 months included manifest refraction, monocular uncorrected and distance corrected visual acuity (UDVA and CDVA), monocular uncorrected and distance corrected intermediate visual acuity (UIVA and DCIVA, at 80 and 66 cm), monocular uncorrected and distance corrected near visual acuity (UNVA and DCNVA, at 40 cm), binocular defocus curve and rotational stability. Results Manifest refraction spherical equivalent and refractive astigmatism were −0.24±0.41D and −0.36±0.36D, respectively. About 79% and 97% of eyes were within ±0.50D and ±1.00D, respectively, and 80% and 96% of eyes were ≤0.50D and ≤1.00D of refractive cylinder, respectively. At distance vision, the mean monocular CDVA was −0.02±0.06 logMAR and 92.93% of eyes showed a CDVA of ≥20/20. At intermediate vision, the mean monocular DCIVA values were 0.10±0.07 and 0.17±0.10 logMAR at 80 cm and 66 cm, respectively; and 96.92% and 88.33% of eyes showed a DCIVA of ≥20/32 at 80 cm and 66 cm, respectively. At near vision, the mean monocular DCNVA was 0.31±0.08 logMAR and 75.44% of eyes showed a DCNVA of ≥20/40. The binocular depth of focus range was approximately 1.50D. The mean absolute IOL rotation was 2.73±2.58 degrees with all eyes having a rotation of <10 degrees. Conclusions Eyes with pre-existing astigmatism implanted with the Isopure Serenity toric IOL showed good distance visual acuity and functional intermediate vision, with high refractive accuracy and good rotational stability following cataract and refractive lens exchange surgery.
S. Daya, Takayuki Akahoshi, Camille Bosc et al.· Clinical Ophthalmology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
